Bookbuilding IPO | ₹6,480 Cr | Listed at BSE, NSE | Mon, Nov 9, 2020 - Wed, Nov 11, 2020
Gland Pharma IPO is a book build issue of ₹6,479.55 crores. The issue is a combination of fresh issue of 0.83 crore shares aggregating to ₹1,250.00 crores and offer for sale of 3.49 crore shares aggregating to ₹5,229.55 crores.
Gland Pharma IPO bidding started from Nov 9, 2020 and ended on Nov 11, 2020. The allotment for Gland Pharma IPO was finalized on Nov 17, 2020. The shares got listed on BSE, NSE on Nov 20, 2020.
Gland Pharma IPO price band is set at ₹1,500 per share. The lot size for an application is 10. The minimum amount of investment required by an retail is ₹15,000 (10 shares) (based on upper price). The lot size investment for sNII is 14 lots (140 shares), amounting to ₹2,10,000, and for bNII, it is 67 lots (670 shares), amounting to ₹10,05,000.
Citigroup Global Markets India Pvt.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Gland Pharma IPO RHP for detailed Information.
IPO Open
Mon, Nov 9, 2020
IPO Close
Wed, Nov 11, 2020
Issue Price
₹1500 per share
Market Cap (Pre-IPO)
₹24,492.42 Cr
| IPO Date | 9 to 11 Nov, 2020 |
| Listed on | Fri, Nov 20, 2020 |
| Face Value | ₹1 per share |
| Price Band | ₹1490 to ₹1500 |
| Issue Price | ₹1500 per share |
| Lot Size | 10 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 4,31,96,968 shares (agg. up to ₹6,480 Cr) |
| Fresh Issue | 83,33,333 shares (agg. up to ₹1,250 Cr) |
| Offer for Sale | 3,48,63,635 shares of ₹1 (agg. up to ₹5,230 Cr) |
| Share Holding Pre Issue | 15,49,49,490 shares |
| Share Holding Post Issue | 16,32,82,823 shares |
| BSE Script Code / NSE Symbol | 543245 / GLAND |
| ISIN | INE068V01023 |
Gland Pharma IPO comprises a total issue size of 4,31,96,968 shares. Out of which, 2,15,98,483 (50.00%) are allocated to QIB, 64,79,546 (15.00%) allocated to NII 1,51,18,939 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Total Issue | Max Allottees |
|---|---|---|---|
| QIB Shares Offered | 2,15,98,483 | 50.00% | NA |
| − Anchor Investor Shares Offered | 1,29,59,089 | 30.00% | NA |
| − QIB (Ex. Anchor) Shares Offered | 86,39,394 | 20.00% | NA |
| NII (HNI) Shares Offered | 64,79,546 | 15.00% | NA |
| Retail Shares Offered | 1,51,18,939 | 35.00% | 15,11,893 |
| Total Shares Offered | 4,31,96,968 | 100.00% |
Investors can bid for a minimum of 10 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 10 | ₹15,000 |
| Retail (Max) | 13 | 130 | ₹1,95,000 |
| S-HNI (Min) | 14 | 140 | ₹2,10,000 |
| S-HNI (Max) | 66 | 660 | ₹9,90,000 |
| B-HNI (Min) | 67 | 670 | ₹10,05,000 |
Gland Pharma IPO raises ₹1,943.86 crore from anchor investors. Gland Pharma IPO Anchor bid date is November 6, 2020.
📝 Anchor Investors Letter (PDF)
| Bid Date | Fri, Nov 6, 2020 |
| Shares Offered | 1,29,59,089 |
| Anchor Portion (₹ Cr.) | 1,943.86 |
| Anchor lock-in period end date for 50% shares (30 Days) | Thu, Dec 17, 2020 |
| Anchor lock-in period end date for remaining shares (90 Days) | Mon, Feb 15, 2021 |
Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.
The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.
Company Strengths
| Period Ended |
|---|
| Amount in ₹ Crore |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding incremental working capital requirements of our Company | 769.50 |
| 2 | Funding capital expenditure requirements of our Company | 168.00 |
| 3 | General corporate purposes | 286.47 |
The Gland Pharma IPO is subscribed 2.06 times on November 11, 2020 6:00:01 PM (Day 3). The public issue subscribed 0.24 times in the retail category, 6.4 times in the QIB category, and 0.51 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 6.4 | 86,39,394 | 5,52,50,350 |
| NII | 0.51 | 64,79,546 | 32,94,470 |
| Retail | 0.24 | 1,51,18,939 | 36,10,850 |
| Total | 2.06 | 3,02,37,879 | 6,21,55,670 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | BRLMs fees and commissions (including underwriting commission, brokerage and selling commission) | 97.34 |
| 2 | Selling commission/processing fee for SCSBs, Sponsor Bank and fee payable to the Sponsor Bank for Bids made by RIBs | 1.04 |
| 3 | Brokerage and selling commission and bidding charges for members of the Syndicate (including their sub-Syndicate Members), Registered Brokers, RTAs and CDPs | 3.12 |
| 4 | Fees payable to the Registrar to the Offer | 0.12 |
| 5 | Fees payable to the other advisors to the Offer | 0.94 |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | 10.27 |
| 7 | Printing and stationery | 1.29 |
| 8 | Advertising and marketing expenses | 9.22 |
| 9 | Fee payable to legal counsels | 10.69 |
| 10 | Miscellaneous | 5.23 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹1,500.00 | ₹1,500.00 |
| Open | ₹1,701.00 | ₹1,710.00 |
| Low | ₹1,701.00 | ₹1,700.00 |
| High | ₹1,850.00 | ₹1,850.00 |
| Last Trade | ₹1,820.45 | ₹1,819.55 |
Gland Pharma IPO is a main-board IPO of 4,31,96,968 equity shares of the face value of ₹1 aggregating up to ₹6,480 Crores. The issue is priced at ₹1500 per share. The minimum order quantity is 10.
The IPO opens on Mon, Nov 9, 2020, and closes on Wed, Nov 11, 2020.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Gland Pharma IPO using UPI as a payment gateway. Zerodha customers can apply in Gland Pharma IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Gland Pharma IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Gland Pharma IPO opens on Mon, Nov 9, 2020 and closes on Wed, Nov 11, 2020.
Gland Pharma IPO lot size is 10, and the minimum amount required for application is ₹15,000.
You can apply in Gland Pharma IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Gland Pharma IPO will be done on Tuesday, November 17, 2020, and the allotted shares will be credited to your demat account by Thu, Nov 19, 2020. Check the Gland Pharma IPO allotment status.
The Gland Pharma IPO listing date is on Fri, Nov 20, 2020.
